Tech Company Financing Transactions

Nereus Pharmaceuticals Funding Round

On 8/9/2007, Nereus Pharmaceuticals raised $45 million in Series D funding from BankInvest BioMedical Venture, Advent International and Alta Partners.

Transaction Overview

Company Name
Nereus Pharmaceuticals
Announced On
8/9/2007
Transaction Type
Venture Equity
Amount
$45,000,000
Round
Series D
Investors

BankInvest BioMedical Venture (Lead Investor) (Jesper Zeuthen)

Advent International (Jason Fisherman)

Alta Partners (Jean Deleage)

Forward Ventures (Standish Fleming)

GIMV

HBM Healthcare Investments (Erich Platzer)

InterWest Partners (Nina Kjellson)

Pacific Venture Partners

Roche Venture Fund

Proceeds Purpose
The proceeds from the financing will be drawn down in two tranches and used to complete Phase I and begin Phase II clinical trials for Nereus' two drug candidates. The first compound, NPI-2358, is being evaluated for the treatment of solid tumors and lymphomas in Phase I clinical trials.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
10480 Wateridge Cir.
San Diego, CA 92121
USA
Phone
(858) 587-4090
Website
www.nereuspharm.com
Email Address
[email protected]
Overview
Nereus Pharmaceuticals is an innovative drug discovery and development company pursuing untapped sources of chemical diversity.
Profile
Nereus Pharmaceuticals LinkedIn Company Profile
Social Media
Nereus Pharmaceuticals Company Twitter Account
Company News
Nereus Pharmaceuticals News
Facebook
Nereus Pharmaceuticals on Facebook
YouTube
Nereus Pharmaceuticals on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Kobi Sethna
  Kobi Sethna LinkedIn Profile  Kobi Sethna Twitter Account  Kobi Sethna News  Kobi Sethna on Facebook
Chief Information Officer
Gary McDaniel
  Gary McDaniel LinkedIn Profile  Gary McDaniel Twitter Account  Gary McDaniel News  Gary McDaniel on Facebook
Chief Medical Officer
Matthew Spear
  Matthew Spear LinkedIn Profile  Matthew Spear Twitter Account  Matthew Spear News  Matthew Spear on Facebook
Chief Scientific Officer
Kenneth Lloyd
  Kenneth Lloyd LinkedIn Profile  Kenneth Lloyd Twitter Account  Kenneth Lloyd News  Kenneth Lloyd on Facebook
Chief Technical Officer
Michael Palladino
  Michael Palladino LinkedIn Profile  Michael Palladino Twitter Account  Michael Palladino News  Michael Palladino on Facebook
VP - Finance
Donald Salz
  Donald Salz LinkedIn Profile  Donald Salz Twitter Account  Donald Salz News  Donald Salz on Facebook
VP - Regulatory Affairs
Howard Holden
  Howard Holden LinkedIn Profile  Howard Holden Twitter Account  Howard Holden News  Howard Holden on Facebook

 

 

Browse more venture capital transactions:

Prev: 8/9/2007: KFx Medical venture capital transaction
Next: 8/9/2007: MetroLight venture capital transaction

 

Share this article

 

About Database of VC Transactions

We do our best to record all VC transactions involving tech companies. VC investment data records reported here come from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.